Melissa Moore, APRN
Primary Care · Hindman, KYNPI 1336571298
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations.
Across 93 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$237
- AstraZeneca$216
- Boehringer Ingelheim$192
- Pfizer$125
- AbbVie$107
- Novartis$97
- plus $617 from 15 others
What the payments were for
- Food & beverage$1,591100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 12 | $237 |
| AstraZeneca(2 entities) | 14 | $216 |
| Boehringer Ingelheim | 13 | $192 |
| Pfizer | 8 | $125 |
| AbbVie | 3 | $107 |
| Novartis | 5 | $97 |
| Lilly USA, LLC | 5 | $88 |
| GSK | 5 | $76 |
| Merck | 4 | $72 |
| Bayer | 4 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| Novo Nordisk | 3 | $52 |
| Vertex | 2 | $42 |
| Evoke Pharma, Inc. | 2 | $35 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Baxter Healthcare | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Genentech USA, Inc. | 2 | $11 |
How this compares
$1,591 in reported general payments places this provider in the 80th percentile of 80 primary care providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 45 | $42,023 |
| FarxigaDapagliflozin Propanediol | 58 | $33,604 |
| EliquisApixaban | 50 | $25,969 |
| JardianceEmpagliflozin | 22 | $22,530 |
| TrulicityDulaglutide | 17 | $16,659 |
| EntrestoSacubitril/Valsartan | 14 | $15,226 |
| Repatha SureclickEvolocumab | 16 | $12,993 |
| RexultiBrexpiprazole | 12 | $8,813 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,539 |
| Praluent PenAlirocumab | 15 | $7,272 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $7,131 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,808 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $6,235 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,907 |
| Ipratropium Bromide | 42 | $2,882 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus | $52 | $42,02345 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $216 | $40,41169 claims |
| Boehringer IngelheimJardiance, Glyxambi | $192 | $29,66134 claims |
| PfizerEliquis | $125 | $25,96950 claims |
| Lilly USA, LLCTrulicity | $88 | $16,65917 claims |
| NovartisEntresto | $97 | $15,22614 claims |
| GSKBreo Ellipta | $76 | $4,90712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 80 primary care providers in Kentucky.
Other primary care in Hindman
- Jessica GoettlLouisville$59K
- Angela ClarkBowling Green$10K
- Tara CoyleShelbyville$7K
- Heather AdamsLexington$7K
- Bridget McKinleyElizabethtown$6K
- Tracy DarlingtonCrestview Hills$6K
- Reagen LoughranLondon$6K
- Jeryl PittmanRichmond$6K
- Samantha FraleyPrestonsburg$3K
- Pamela PhelpsMorgantown$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.